PharmiWeb.com - Global Pharma News & Resources

PwToday Stories

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Amneal Pharmaceuticals, Inc. (Amneal) with regard to Levothyroxine Sodium Tablets USP.  Under the agreement, Amneal will be Lannett's sole customer for Levothyroxine Sodium beginning December 1, 2018 through March 23, 2019, and will re-sell the products to its customers.  Lannett will receive an upfront payment of $50 million, other terms of the transaction were not disclosed. As previously announced, Lannett's distribution agreement with Jerome Stevens Pharmaceuticals (JSP), which includes Levothyroxine Sodium Tablets USP, expires on March 23, 2019 and will not be renewed. "This agreement benefits all parties, including and importantly patients and customers who can be assured of a…
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ: MYL) ("Mylan") today announced that the U.S. Food and Drug Administration (FDA) has approved the  New Drug Application (NDA) for YUPELRITM (revefenacin) inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI, a long-acting muscarinic antagonist (LAMA), is the first and only once-daily, nebulized bronchodilator approved for the treatment of COPD in the US. The companies expect YUPELRI to be available to COPD patients in the US before the end of the year. COPD is the third leading cause of death and the fourth leading cause of hospital readmissions in the US, affecting approximately 16 million Americans. "Long-acting muscarinic a…
-        Upfront payment of US$15m -        Up to US$80m of development milestone payments -        Mid teen percentage profit share arrangement for each portfolio product Chippenham, UK – 08 November 2018: Vectura Group plc (LSE: VEC) ("Vectura", "the Group"), today announces signing an agreement with Hikma Pharmaceuticals PLC ("Hikma") for the global development and commercialisation of generic versions of GSK’s Ellipta® portfolio, utilising Vectura’s proprietary Open-Inhale-Close dry powder inhaler device. Following interactions with US FDA, the Open-Inhale-Close dry powder inhaler device has the potential to be developed as an AB-rated substitutable drug-device combinati…
American Healthcare Investors and Griffin Capital Company, LLC, the co-sponsors of Griffin-American Healthcare REIT IV, Inc., announced today that the REIT completed the acquisition of 13 healthcare buildings in five states for an aggregate contract purchase price of approximately $178.4 million during the third quarter of 2018. The acquisitions were comprised of three medical office buildings, two senior housing facilities and eight skilled nursing facilities. "We continue to acquire accretively for the quickly growing portfolio of Griffin-American Healthcare REIT IV," said Stefan Oh, executive vice president of acquisitions for American Healthcare Investors and Griffin-American Healthcare REIT IV. "Including acquisitions completed during and after the close of the third quarter, our p…
WELL Health Technologies Corp. (TSX.V: WELL) (the "Company or "WELL"), a company focused on consolidating and modernizing clinical and digital assets within the primary healthcare sector, is pleased to announce that it has entered into a subscription agreement with Circle Medical Inc. ("Circle Medical") to invest $200,000 USD in the Silicon Valley based digital health company's latest round of financing. "We are pleased to become shareholders of Circle Medical a company that has been successful in developing technology applications that have contributed to a more digital and convenient patient experience," said Hamed Shahbazi, Chairman and CEO of WELL Health Technologies.  "We look forward to considering various ways we can unlock value together as both companies evolve and augment…
Medela LLC announced today that Apria Healthcare, one of the nation's largest providers of home healthcare and equipment services, will begin distributing Medela's negative pressure wound therapy (NPWT) product line on a national basis. Under the terms of the agreement, Apria will expand its wound care portfolio to include the full line of Medela's negative pressure wound therapy products, including the Invia® NPWT System with FitPad.  Apria will offer the Medela products through its more than 300 local branch offices and its nearly 1,900 commercial payers and preferred provider arrangements with integrated health systems across the country. "I am excited about bringing Apria and Medela together," said Kevin Ackermann, vice president of healthcare for Medela USA.  "By offer…
LifeArc, a medical research charity, has signed an agreement to review Asthma UK’s research portfolio, aiming to identify promising projects and results which are most suited to development into treatments.  LifeArc will also advise on strategies to deliver that development.  LifeArc’s expertise in intellectual property (IP) protection, development and management will allow Asthma UK to translate its research funding into maximum benefit for patients. Dr Erika Kennington, Head of Research at Asthma UK, said: “An estimated 5.4million people in the UK live with asthma and despite the prevalence of the condition, there is still much that isn’t understood. Asthma can leave people gasping for breath and at risk of a potentially life-threatening asthma attack. Research enables a bet…
Novartis announced additional brolucizumab Phase III results from year two that reaffirmed its positive year one findings. Brolucizumab met its primary endpoint of non-inferiority versus aflibercept in best corrected visual acuity (BCVA) and exhibited superiority in key retinal outcomes at year one (48 weeks)1,2. Secondary endpoints at year two (96 weeks) reaffirmed superiority of brolucizumab 6 mg in reduction of retinal fluid, an important marker of disease activity in patients with neovascular age-related macular degeneration (nAMD)1,3. Approximately 20 to 25 million people are affected by nAMD, also known as wet AMD, a leading cause of blindness worldwide4,5.   The year two HAWK and HARRIER findings demonstrated that fewer patients with nAMD had intra-retinal fluid (IRF) and…
EB8018, the lead investigational candidate, targets Crohn’s disease with potential for other GI disorders ENTEROME SA, a clinical-stage biotech company developing innovative therapies to treat microbiome-associated diseases with a focus on auto-immune disease and cancer, has entered into a global licensing, co-development and co-promotion agreement with Takeda Pharmaceutical Company Limited (“Takeda”). The agreement covers Enterome’s lead investigational drug candidate EB8018 in patients with Crohn’s disease, with the potential to expand to other gastrointestinal (GI) disorders and liver diseases.   “We are delighted to sign this agreement for EB8018, our most advanced candidate that represents a non-antibiotic, non-steroidal, non-immunomodulatory approach for the treatment o…
Selexis SA and Berkeley Lights, Inc. today announced a collaboration around the acquisition of Berkeley Lights’ Beacon® optofluidic platform. The partners will leverage the technology to accelerate cell line development (CLD) with the Selexis SUREtechnology Platform™. Selexis scientists have extensively evaluated the Beacon technology and will now further incorporate it into the SUREtechnology Platform workflow. Utilizing the Beacon’s optofluidic and single cell analysis technology, the Selexis team has significantly shortened the time required to identify and select the optimal cell line manufacturing clones within the CLD process.   “We are very enthusiastic about the timeline advantages that the Beacon platform will bring to our SUREtechnology Platform,” said Igor Fisch, PhD,…
LNC Therapeutics, a French biotech company specializing in gut microbiome-based drug discovery, today announced that it has signed an exclusive license agreement with Cornell University (Ithaca, NY, USA ) for its Christensenella patent family. Christensenellais a recently discovered family of gut bacteria. Considered a keystone taxon in the human gut microbiome, it represents a major opportunity in the fight against obesity, metabolic disorders and other high-impact diseases. Christensenella and microbiome modulation is an innovative approach with the potential to unlock a wide range of therapeutic applications. By securing a license for the Christensenella patent, LNC has bolstered its strategy for developing innovative therapeutic approaches based on this new family of bacteri…
eXmoor pharma and MeiraGTx are delighted to announce an extension to their strategic collaboration.   eXmoor is providing process development services from its Commercialisation Laboratories at Future Space, Bristol. Two streams of work have focused on development of the MeiraGTx adherent and suspension cell process platforms and have demonstrated yield improvement as well as scale up towards commercial supply.   This collaboration is the next step in the relationship following eXmoor’s assistance in the design and implementation of MeiraGTx’s new Gene Therapy Facility in central London. Managing director of eXmoor, Angela Osborne said “The synergy with the Consultancy business keeps our Lab Team focused on the end game of GMP manufacturing and I’m very pleased tha…
The European specialty pharmaceutical company launches its new name to support its strategic vision   Neuraxpharm, a leading European specialty pharmaceutical company, is pleased to announce its new name, having rebranded from NuPharm Group. This exciting next chapter for the company positions Neuraxpharm as a single and differentiated CNS-oriented firm within the European pharmaceutical industry. Neuraxpharm develops and commercializes branded and generic pharmaceuticals for the treatment of disorders that affect the central nervous system (CNS). With over 100 CNS molecules, the company offers a wide range of effective, differentiated and affordable CNS treatment options to patients, healthcare professionals and industry partners. Neuraxpharm has a direct presence in Germany…
·        Deal includes global rights to pegfilgrastim biosimilar, Pelmeg® with a potential global market worth $4.5bn1 ·        Mundipharma acquires 100% ownership from parent company Infarco ·        As a leader in biosimilars in Europe, today’s deal deepens Mundipharma’s biosimilars platform beyond commercial excellence to development ·        Mundipharma estimates that through its existing partnership with Celltrion – Remsima® and Truxima® have saved healthcare systems approximately €330m2   Cambridge, UK, 10th October 2018.  The Mundipharma global network of independent associated companies has today added development capab…
Hatfield, UK | Porto, Portugal | 08 October 2018 – Bial and Eisai have today announced new sub-analysis data from the Euro-Esli study, that confirms that the effectiveness of eslicarbazepine acetate monotherapy is significantly greater compared with eslicarbazepine acetate as adjunctive therapy in adults with focal-onset epilepsy based on clinical practice.[1] Whilst this may be expected, given that patients managed on monotherapy will tend to be less refractory to treatment, it provides real-world substantiation for the value of eslicarbazpine acetate as monotherapy in newly diagnosed patients. The data, which add to the body of evidence on eslicarbazepine acetate as monotherapy were published today in Acta Neurologica Scandinavica.1   The Euro-Esli study presents the largest c…
Allergan plc (NYSE: AGN) today announced the initiation of two global clinical research programs for brazikumab, an investigational drug being studied for inflammatory bowel disease (IBD). INTREPID (Crohn's disease) and EXPEDITION (ulcerative colitis), will evaluate the safety and efficacy of brazikumab and will investigate the role of biomarkers in determining a predictive response of brazikumab in patients with IBD. They are the first active comparator studies of an IL-23 inhibitor therapy in IBD to evaluate biomarkers as potential predictors of treatment response and the first randomized comparison of an IL-23 inhibitor versus HUMIRA® (adalimumab) in Crohn's disease and ENTYVIO® (vedolizumab) in ulcerative colitis. Despite advancements in IBD treatments, up to 80 percent of pati…
GW Pharmaceuticals plc (Nasdaq: GWPH, "GW," and the “Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the pricing of an underwritten public offering by the Company. GW will issue 1,900,000 American Depositary Shares (“ADSs”), representing 22,800,000 ordinary shares of GW, at a price to the public of $158.00 per ADS on the Nasdaq Global Market, raising gross proceeds of approximately $300 million (before deducting underwriting discounts, commissions and offering expenses).  GW has granted the underwriters a 30-day option to purchase up to an additional 285,000 ADSs at the public offering price less underwriting discounts and commissions.  Closing of th…
·         Arix co-leads a $58 million Series A investment in new Group Business, VelosBio Inc., bringing core portfolio1 to 15 companies Arix commits $11 million (£8.4 million)2 for 11.2% ownership stake Co-investment with strategic partner Takeda and leading venture capital investors Arix further strengthens position in oncology; investment in VelosBio increases oncology portfolio3 to 5   Arix Bioscience plc (LSE: ARIX) (“Arix” or the “Company”), a global healthcare and life science company supporting medical innovation, today announces that it has invested in new Group Business, VelosBio Inc. (“VelosBio”), a next-generation oncology company, developing novel antibody-drug conjugates (“ADCs”) to treat haematological cancers and solid…
WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing and I-Mab Biopharma ("I-Mab"), a biotech company focusing exclusively on innovative biologics in immuno-oncology and auto-immune diseases, jointly announce today that I-Mab has expanded strategic collaboration with WuXi Biologics and licensed proprietary WuXiBody™ Platform to develop three bispecific antibodies. WuXi Biologics will also be the exclusive partner to develop and manufacture these bispecifics. Under the terms of the agreement, I-Mab has rights to use the proprietary WuXiBody™ Platform to research, develop and commercialize three bispecific antibodies generated from I-MAB's proprietary pipeline. WuXi…
Nutriband Inc. (OTCQB: NTRB), is pleased to announce it has signed the definitive acquisition agreement to acquire Carmel Biosciences, Inc.  The acquisition is expected to be valued at approximately $2,700,000 and will be paid in company stock in the amount of 350,000 restricted common shares. According to the deal, Nutriband will acquire the NDA and ownership rights to FDA approved Prexxartan™, the ownership and rights to develop and market Carmel's pipeline including CAR-509, CAR-510, CAR-511 and CAR-512 currently in Pre IND phase plus rights to Carmel's clinically tested nutraceutical line.  This includes MET-191, a nutritional supplement which has demonstrated benefit of lipid management, appetite control, and weight management, while improving factors that contribute to t…